Alzamend Neuro, Inc.

About Alzamend Neuro, Inc.

Alzamend Neuro is a development stage biotechnology company which has licensed a patented mutant peptide developed by Dr. Chuanhai Cao at the college of Pharmacy of the University of South Florida (USF) and USF- Health Byrd Alzheimer’s Institute to develop a cell based therapeutic vaccine as an immunotherapy to prevent or slowdown Alzheimer’s disease. This therapy is not only target on the pathological molecule that is associated to AD, but also is able to fix the impaired immune system associated to AD development
YEAR FOUNDED:
2016
LEADERSHIP:
CEO: Phil Mansour
CTO: William B. Horne
Chairman: Milton “Todd” Ault
CAREER:
Please click here for Alzamend Neuro's job opportunities.